Pipeline

Modality	Code	Classification	Indication	Discovery
RNA Therapeutics (ASO)	ATB-320	Combination with Chemotherapy	Pancreatic Cancer	Discovery Non-Clinical Phase 1 Phase 2 Phase 3 NDA Phase 1 Approved in Australia
	ATB-720	First-in-Class, Immune Modulator	Atopic Dermatitis & Psoriasis	Discovery Non-Clinical Phase 1 Phase 2 Phase 3 NDA Discovery
	ATB-810	First-in-Class, Immune Modulator	Neurodegenerative Diseases (ALS & MS)	Discovery Non-Clinical Phase 1 Phase 2 Phase 3 NDA Discovery
Small Molecule	ATB-101	Fixed-Dose Combination (FDC)	Type 2 Diabetes + Hypertension	Discovery Non-Clinical Phase 1 Phase 2 Phase 3 NDA Phase 3

Privacy Policy
Headquarters.#302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do, 28610, Republic of Korea
R&D Center.#510 Signature Gwanggyo Knowledge Business Center 37, Poeun-daero 59beon-gil,
Suji-gu, Yongin-si, Gyeonggi-do, 16864, Republic of Korea
- T.043-233-9373
- F.043-233-9374
- E.info@autotelic.co.kr